Divarasib
Appearance
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H32ClF4N7O2 |
| Molar mass | 622.07 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Divarasib (GDC-6036) is an experimental anticancer drug which acts as an inhibitor of the G12C mutant form of Kirsten rat sarcoma virus oncogene homologue (KRAS), an oncogene commonly present in several forms of cancer. It is in clinical trials studying its toxicity and efficacy against various types of cancer, including colorectal cancer, lung cancer and advanced solid tumors.[1][2][3] In a phase 3 trial evaluating efficacy as second-line therapy for patients with metastatic KRAS G12C mutant non-small cell lung cancer, it demonstrated superior progression-free survival and overall survival compared with a control arm of either sotorasib or adagrasib.[4]
See also
[edit]References
[edit]- ↑ Ros J, Vaghi C, Baraibar I, Saoudi González N, Rodríguez-Castells M, García A, et al. (March 2024). "Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver". International Journal of Molecular Sciences. 25 (6): 3304. doi:10.3390/ijms25063304. PMC 10970443. PMID 38542278.
- ↑ Brazel D, Nagasaka M (May 2024). "Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC". Targeted Oncology. 19 (3): 297–301. doi:10.1007/s11523-024-01055-y. PMC 11111488. PMID 38739329.
- ↑ Tenekeci AK, Unal AA, Ceylan F, Nahit Sendur MA (2024). "An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer". Future Oncology. 20 (37). London, England: 3019–3038. doi:10.1080/14796694.2024.2407280. PMC 11572139. PMID 39360933.
- ↑ Skoulidis F, Ahn MJ, Gadgeel S, Popat S, Reinmuth N, van Veggel B, et al. (October 2026). "Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC". The New England Journal of Medicine. 0 NEJMoa2605703. Massachusetts Medical Society. doi:10.1056/NEJMoa2605703. PMID 42929675.